|
17I223,300 IU/3ML
現行藥物外觀
中文名:諾和密斯30筆型胰島素
廠牌:NOVA NORDISK A/S
|
| Product
name |
NOVOMIX
30 PENFILL |
|
| Dosage
form |
|
| Indications |
|
| Administration
& Dosage |
Insulin preparation |
Composition |
Onset
(hr) |
Peak
(hr) |
Duration
(hr) |
Admini-stration |
Rapid-Acting |
Novorapidâ Penfill |
Insulin Aspart |
10-20 min |
1-3 |
3-5 |
IV, SC |
Short- Acting |
Insulin Actrapidâ |
Insulin Regular |
within 30 min |
1.5-3.5 |
7-8 |
IV, SC |
Intermediate- Acting |
Insulin
Insulatardâ |
Insulin NPH |
within
1.5 |
4-12 |
24 |
SC |
Insulin Mixture |
Novomixâ
Penfill |
30% Insulin Aspart+ 70% Insulin Aspart Protamine |
10-20 min |
1-4 |
24 |
SC |
Long- acting |
Lantusâ
SoloStar Pen |
Insulin Glargine |
3-4 |
Flat |
24 |
SC |
Levemirâ
FlexPen |
Insulin Detemir |
3-4 |
Flat |
5.7-23.2 |
SC |
|
|
| Contraindication |
hypoglycemia;
hypersensitivity to insulin-aspart/ insulin-aspart protamine products. |
|
| Precaution |
|
| Adverse
reaction |
M: Hypoglycemia; weight gain.
R: Edema; lipoatrophy at injection site; lipohypertrophy at injection site.
|
|
| Drug
Interaction |
|
| Pregnancy
Category |
|
| Notes |
| The risk of lipoatrophy may be reduced by injecting insulin into the periphery of the atrophic site in order to restore subcutaneous adipose tissue. The risk of lipohypertrophy may be decreased by rotating injection sites. |
|
